We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Major histocompatibility complex Class II-based therapy for stroke.
- Authors
Gonzales-Portillo, Bella M.; Jea-Young Lee; Vandenbark, Arthur A.; Offner, Halina; Borlongan, Cesario V.
- Abstract
This review discusses the potential of major histocompatibility complex (MHC) Class II constructs as stroke therapeutics. We focus on the delivery of MHC Class II construct, DRmQ, as a safe and effective treatment for ischemic stroke. DRmQ was observed to attenuate behavioral deficits and decrease microglia activation and proinflammatory cytokines, illustrating its ability to mitigate the secondary cell death following stroke. Similar anti-neuroinflammation treatments, such as transplantation of mesenchymal stem cells and mitochondrial transfers, are briefly discussed to provide further support that sequestration of inflammation stands as a robust therapeutic target for stroke.
- Subjects
MAJOR histocompatibility complex; STROKE treatment; CYTOKINES; CELL death; MESENCHYMAL stem cells; STEM cell treatment
- Publication
Brain Circulation, 2021, Vol 7, Issue 1, p37
- ISSN
2394-8108
- Publication type
Article
- DOI
10.4103/bc.bc_16_21